[1]叶宗媛,许 雪,胡 娟.肉瘤滤过性毒菌致癌同源体B1 V600E基因及生长分化因子15表达变化与甲状腺乳头状癌患者淋巴结转移及预后关系研究[J].陕西医学杂志,2023,52(12):1765-1769.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.030]
　YE Zongyuan,XU Xue,HU Juan.Relationship between expression of BRAF V600E gene,GDF-15 and lymph node metastasis,prognosis in patients with papillary thyroid carcinoma[J].,2023,52(12):1765-1769.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.030]
点击复制

肉瘤滤过性毒菌致癌同源体B1 V600E基因及生长分化因子15表达变化与甲状腺乳头状癌患者淋巴结转移及预后关系研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
52
期数:
2023年12期
页码:
1765-1769
栏目:
临床病理
出版日期:
2023-12-05

文章信息/Info

Title:
Relationship between expression of BRAF V600E gene,GDF-15 and lymph node metastasis,prognosis in patients with papillary thyroid carcinoma
作者:
叶宗媛; 许 雪; 胡 娟
(合肥市第一人民医院病理科,安徽 合肥 230061)
Author(s):
YE Zongyuan; XU Xue; HU Juan
(Department of Pathology,the First People's Hospital of Hefei,Hefei 230061,China)
关键词:
甲状腺乳头状癌;  肉瘤滤过性毒菌致癌同源体B1 V600E基因;  生长分化因子-15;  淋巴结转移;  预测价值
Keywords:
Papillary thyroid carcinoma;  V-raf murine sarcoma viral oncogene homolog B1 V600E gene;  Growth differentiation factor 15;  Lymph node metastasis;  Predictive value
分类号:
R 736.1
DOI:
DOI:10.3969/j.issn.1000-7377.2023.12.030
文献标志码:
A
摘要:
目的:探究肉瘤滤过性毒菌致癌同源体B1(BRAF)V600F基因及生长分化因子15(GDF-15)表达变化与甲状腺乳头状癌(PTC)患者淋巴结转移及预后的关系。方法:收集出现淋巴结转移的PTC患者60例作为研究组,收集同期无淋巴结转移的PTC患者53例作为对照组,均测定BRAF V600E基因及GDF-15表达。比较两组患者BRAF V600E基因及GDF-15表达差异。分析两指标与研究组患者临床特征间的关系。分析两指标对PTC患者淋巴结转移的预测价值及与患者预后间的关系。结果:研究组患者BRAF V600E基因突变率及GDF-15阳性表达率高于对照组(均P<0.05)。BRAF V600E基因突变及GDF-15阳性表达与淋巴结转移PTC患者肿瘤直径和是否包膜侵犯有关(均P<0.05)。BRAF V600E基因突变及GDF-15阳性表达对PTC患者淋巴结转移均具有一定的预测价值,两项联合的预测价值更高(均P<0.05)。BRAF V600E基因突变患者累积无进展生存率低于BRAF V600E基因未突变患者,GDF-15阳性表达患者累积无进展生存率低于GDF-15阴性表达患者(均P<0.05)。结论:PTC患者BRAF V600E基因及GDF-15表达变化与PTC患者淋巴结转移及预后关系密切,均可能参与了PTC病情发生及进展过程,可以作为患者病情评估及预后的预测指标。
Abstract:
Objective:To investigate the relationship between expression of v-raf murine sarcoma viral oncogene homolog B1(BRAF)V600E gene,growth differentiation factor 15(GDF-15)and lymph node metastasis,prognosis in patients with papillary thyroid carcinoma(PTC).Methods:Sixty PTC patients with lymph node metastasis were collected as the study group,and 53 PTC patients without lymph node metastasis were collected as the control group.The expression of BRAF V600E gene and GFD-15 were measured in both groups.The expression differences of BRAF V600E gene and GDF-15 between the two groups were compared.The relationship between the two indicators and the clinical characteristics of the study group was analyzed.The predictive value of the two indicators for lymph node metastasis in PTC patients and their relationship with the prognosis of patients were analyzed.Results:The mutation rate of BRAF V600E gene and the positive expression rate of GDF-15 in the study group were higher than those in the control group(all P<0.05).BRAF V600E gene mutation and GDF-15 positive expression were related to tumor diameter and capsular invasion in PTC patients with lymph node metastasis(all P<0.05).Both BRAF V600E mutation and GDF-15 positive expression had a certain predictive value for lymph node metastasis in PTC patients,and the combination of the two had a higher predictive value(all P<0.05).The cumulative progression-free survival rate of patients with BRAF V600E gene mutation was lower than that of patients without BRAF V600E gene mutation,and the cumulative progression-free survival rate of patients with GDF-15 positive expression was lower than that of patients with GDF-15 negative expression(all P<0.05).Conclusion:The expression of BRAF V600E gene and GDF-15 in PTC patients is closely related to lymph node metastasis and prognosis,which may be involved in the occurrence and progression of PTC.They can be used as indicators for disease evaluation and prognosis of PTC patients.

参考文献/References:

[1] 傅 强,黄学阳,王建春,等.养阴散结汤辅助治疗分化型甲状腺癌疗效及对患者术后甲状腺、免疫功能和血清学指标的影响[J].陕西中医,2022,43(8):1029-1031,1036.
[2] Yan T,Qiu W,Song J,et al.ARHGAP36 regulates proliferation and migration in papillary thyroid carcinoma cells[J].J Mol Endocrinol,2021,66(1):1-10.
[3] 房 芹,白玉勤.甲状腺乳头状癌肿瘤出芽情况与临床病理特征相关性研究[J].陕西医学杂志,2021,50(7):882-885.
[4] 路振凯,房国伟,王经武,等.基于mTOR/p70S6K信号通路探讨中医药治疗甲状腺恶性肿瘤作用机制进展[J].陕西中医,2022,43(3):402-404.
[5] 刘 颖,查卫娜,杨晓琳,等.甲状腺乳头状癌患者血清miR-34a-5p、miR-4709-3p水平变化及其诊断效能[J].山东医药,2022,62(32):56-59.
[6] 石维超,张少波.甲状腺癌病理微血管密度与颈部淋巴结转移相关性研究[J].陕西医学杂志,2022,51(11):1449-1452.
[7] Han Y,Yu X,Yin Y,et al.Identification of potential BRAF inhibitor joint therapy targets in PTC based on WGCAN and DCGA[J].J Cancer,2021,12(6):1779-1791.
[8] 鲁 涛,高 洁,周良锐,等.甲状腺癌RAS/BRAF/TERT基因突变与临床病理特征的关系[J].诊断病理学杂志,2020,27(4):250-254.
[9] 袁丽侠,郭 剑,张 玲,等.结直肠癌患者血清GDF-15、LAMB1、ULBP2水平与临床病理特征和预后的关系及其诊断价值[J].海南医学,2021,32(19):2480-2483.
[10] 黄江梅,肖 芳,陈艳昕,等.子宫颈鳞状细胞癌中GDF-15与EMT相关蛋白的表达及相关性[J].临床与实验病理学杂志,2019,35(9):1090-1092.
[11] 中华医学会内分泌学分会.甲状腺结节和分化型甲状腺癌诊治指南[J].中华核医学与分子影像杂志,2013,33(2):96-115.
[12] Scheffel RS,Decristo AP,Romitti M,et al.The BRAFV600E mutation analysis and risk stratification in papillary thyroid carcinoma[J].Arch Endocrinol Metab,2021,64(6):751-757.
[13] 刘 威,彭 梅,姜 凡,等.超声检查联合基因及血清检测预测甲状腺微小乳头状癌的侵袭性[J].中国超声医学杂志,2020,36(12):1071-1074.
[14] 陆 婷,张娟娟,王晚璞,等.卵巢低级别浆液性肿瘤中KRAS、NRAS、PIK3CA、BRAF突变及其与患者临床病理特征和激素表达的相关性分析[J].解放军医学杂志,2022,47(8):809-816.
[15] Liu S,Liu C,Zhao L,et al.A prediction model incorporating the BRAFV600E protein status for determining the risk of cervical lateral lymph node metastasis in papillary thyroid cancer patients with central lymph node metastasis[J].Eur J Surg Oncol,2021,47(11):2774-2780.
[16] 肖 庆,唐 亮,罗 鑫.伴BRAF V600E突变的甲状腺乳头状癌超声图像特征及其淋巴结转移风险分析[J].临床超声医学杂志,2023,25(4):315-319.
[17] 姬 巍,董 健,昌 红,等.甲状腺乳头状癌患者临床病理特征和BRAF V600E基因突变对其颈部淋巴结转移的影响[J].吉林大学学报:医学版,2022,48(4):995-1002.
[18] Zhou SL,Guo YP,Zhang L,et al.Predicting factors of central lymph node metastasis and BRAFV600E mutation in Chinese population with papillary thyroid carcinoma[J].World J Surg Oncol,2021,19(1):211-220.
[19] Tao Y,Wang F,Shen X,et al.BRAF V600E status sharply differentiates lymph node metastasis-associated mortality risk in papillary thyroid cancer[J].J Clin Endocrinol Metab,2021,106(11):3228-3238.
[20] Reyes I,Reyes N,Suriano R,et al.Gene expression profiling identifies potential molecular markers of papillary thyroid carcinoma[J].Cancer Biomark,2019,24(1):71-83.
[21] 毕晓峰,张 超,李 茉,等.血清GDF15诊断及筛查结直肠癌的临床价值[J].中国肿瘤,2020,29(12):970-975.
[22] 高 超,郑 晨.血清GDF-15、CTCs在肝细胞癌患者中的表达及与预后的关系[J].检验医学与临床,2023,20(7):951-956.
[23] Breen DM,Kim H,Bennett D,et al.GDF-15 neutralization alleviates platinum-based chemotherapy-induced emesis,anorexia,and weight loss in mice and nonhuman primates[J].Cell Metab,2020,32(6):938-950.
[24] 胡丽君,曾凡思.血清生长分化因子15水平在肾细胞癌诊断和预后中的临床意义[J].国际泌尿系统杂志,2022,42(3):466-470.
[25] Fang L,Li F,Gu C.GDF-15:A multifunctional modulator and potential therapeutic target in cancer[J].Curr Pharm Des,2019,25(6):65-662.
[26] 倪志强,王永恒,彭书旺,等.生长分化因子15在甲状腺乳头状癌中的表达及其临床意义[J].肿瘤研究与临床,2021,33(4):282-286.
[27] Kang YE,Kim JM,Lim MA,et al.Growth differentiation factor 15 is a cancer cell-induced mitokine that primes thyroid cancer cells for invasiveness[J].Thyroid,2021,31(5):772-786.

相似文献/References:

[1]杜 静,袁 勇△,陆建荣,等.CD10在甲状腺肿瘤组织中的表达及检测临床意义*[J].陕西医学杂志,2019,(2):248.
　DU Jing,YUAN Yong,LU Jianrong,et al.Expression and significance of CD10 in thyroid neoplasms[J].,2019,(12):248.
[2]房 芹,白玉勤.甲状腺乳头状癌肿瘤出芽情况与临床病理特征相关性研究[J].陕西医学杂志,2021,50(7):882.[doi:DOI:10.3969/j.issn.1000-7377.2021.07.030]
　FANG Qin,BAI Yuqin.Correlation between tumor budding and clinicopathological features of papillary thyroid carcinoma[J].,2021,50(12):882.[doi:DOI:10.3969/j.issn.1000-7377.2021.07.030]
[3]吴海滨,赵爱国,苗雅云,等.甲状腺乳头状癌组织中肿瘤转移相关基因1、叉头翼螺旋转录因子3水平变化与临床病理特征及淋巴转移的关系[J].陕西医学杂志,2023,52(5):613.[doi:DOI:10.3969/j.issn.1000-7377.2023.05.027]
　WU Haibin,ZHAO Aiguo,MIAO Yayun,et al.Relationship between changes of MTA1,FOXP3 levels and clinicopathological features,lymph node metastasis in patients with papillary thyroid carcinoma[J].,2023,52(12):613.[doi:DOI:10.3969/j.issn.1000-7377.2023.05.027]
[4]高文彩,王 玲,吴慧敏,等.经口腔前庭入路腔镜甲状腺切除术在甲状腺乳头状癌治疗中的应用价值研究[J].陕西医学杂志,2024,(3):344.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.012]
　GAO Wencai,WANG Ling,WU Huimin,et al.Application value of transoral endoscopic thyroidectomy vestibular approach in treatment of papillary thyroid carcinoma[J].,2024,(12):344.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.012]

备注/Memo

备注/Memo:
基金项目:安徽省卫生健康委员会科研项目(AHWJ2021A081)
更新日期/Last Update: 2023-12-05